1. Home /
  2. Biotechnology

Biotechnology

Reata Shares Jump on Drug-Study Results

Reata Shares Jump on Drug-Study Results

Stock gains in after-hours trading after phase II test results meet primary endpoint for a treatment of a rare genetic disease.

A Quick Look at 2 Positive Looking Biotech Plays

A Quick Look at 2 Positive Looking Biotech Plays

Checking on the charts of InMode and BioLife Solutions.

Alphabet Is Cheap Now, but It Won't Remain This Inexpensive Forever

Alphabet Is Cheap Now, but It Won't Remain This Inexpensive Forever

Alphabet is one of the best tech names to invest in, with strong cash flows and a modest valuation.

Here Are Several Promising Rare Disease Stocks

Here Are Several Promising Rare Disease Stocks

These small biotech concerns are undervalued.

RA Pharmaceuticals Soars on Deal to Be Acquired for $2.1 Billion

RA Pharmaceuticals Soars on Deal to Be Acquired for $2.1 Billion

Shares of biotech company Ra Pharmaceuticals more than double after Belgian-based biotech firm UCB announces it is acquiring the company for $2.1 billion in cash.

I'm Unapologetically Overweight in These 2 Sectors

I'm Unapologetically Overweight in These 2 Sectors

The two are homebuilding and biotech, and there are stocks within those sectors where I've parked my money.

Nektar Shares Drop After Double Downgrade to Sell at Goldman Sachs

Nektar Shares Drop After Double Downgrade to Sell at Goldman Sachs

Goldman also slashes its one-year price target by nearly two-thirds on expectations that Nektar's in-the-works cancer treatment won't generate revenue anytime soon.

Qiagen Tumbles on Sales Warning, CEO Departure

Qiagen Tumbles on Sales Warning, CEO Departure

Shares of Qiagen slide after the company warns its third-quarter sales will be lower than expected and that its CEO is resigning.

Sage Therapeutics Is Pointed Down So We Are In No Rush to Buy

Sage Therapeutics Is Pointed Down So We Are In No Rush to Buy

Let's check and see if the charts and indicators suggest where prices might bottom out.

Lantheus and Progenics Sink After Striking All-Stock Deal

Lantheus and Progenics Sink After Striking All-Stock Deal

Lantheus will acquire oncology medicine developer Progenics Pharmaceuticals in an all-stock deal.